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Abstract 
Interferons play a part in the negative control of cell proliferation of mammalian cells. Here a natural interferon has been isolated from 
soluble proteins secreted by secondary murine embryonic fibroblasts using Blue Sepharose chromatography, immunoaffinity exclusion 
and Q Sepharose ion exchange fractionation. Partial amino acid sequencing assigns it to the interferon a family. Its biological and 
physico-chemical properties ingle it out from all other murine a interferons. The embryonic interferon has stronger antiproliferative 
activity, is acid labile, has stronger affinity for Blue Sepharose and weak affinity for antibodies which recognise other murine interferon a 
subtypes. 
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1. Introduction 
Interferons (IFNs) are a heterologous family of multi- 
functional cytokines who~'~e biological activities include 
negative control of cell replication and cell differentiation 
[1]. Several natural IFNs have been characterized and 
novel species have been produced by genetic manipulation 
with a view to selecting IFNs with altered functional 
properties [2-4] including antiproliferative activity. Signif- 
icantly, differences in growth inhibitory properties between 
recombinant I FNas  have been noted [5] but there is no 
information on the differential growth inhibitory properties 
of the naturally occurring endogenous IFNs which have 
been shown to play a part in the control of cell prolifera- 
tion. In previous work we found that in normal murine 
embryonic fibroblasts (MEFs), neutralization of endoge- 
nously produced IFNs by specific antibodies results in the 
shortening of the cell cycle and have mapped the control- 
ling effect to the second part of G1 [6,7]. Here we report 
that a natural murine (mu) IFNa subtype isolated from 
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embryonic ells differs in physico-chemical nd antiprolif- 
erative properties from other murine IFNas.  
2. Materials and methods 
Cell cultures. Secondary cultures of MEFs from C57 BI 6 
mice were grown to confluence in Eagle's BHK medium 
containing 10% v /v  newborn calf serum in an atmosphere 
of 5% CO 2 in air. For growth experiments cells were 
trypsinised and seeded at a density of 5 × 10 4 cel ls/cm 2
in 25-cm 2 flasks in Eagle's BHK medium with 5% foetal 
calf serum and 5% CO 2 in air and incubated at 37°C. 
Population distribution during the cell cycle was assessed 
by FACS analysis. Details of these procedures have been 
described previously [7]. 
I FN  puri f icat ion. Constitutive interferon activity was 
isolated from soluble proteins secreted by confluent sec- 
ondary MEFs into serum-free medium (SFM) during a 
16-h period of incubation at 37°C, according to a protocol 
reported previously [8]. For IFN induction, confluent sec- 
ondary cells were treated with 16.6 /zg/ml  of poly I:poly 
C and 33.3 /xg/ml DEAE dextran for 4 h at 37°C, then 
washed with SFM and incubated in SFM for 16 h at 37°C. 
Supernatants were concentrated 10-fold in dialysis bags 
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using PEG 20000 and run twice through Blue Sepharose 
CL-6B (Pharmacia) columns pre-equilibrated with phos- 
phate-buffered saline (PBS). The columns were washed 
with PBS and elution was carried out firstly using 1.5 M 
NaC1 in PBS and then, after further washing with PBS, 
using 40% v /v  ethylene glycol in 1.5 M NaC1 in PBS. 
The eluted fractions were collected in volumes of 1 ml and 
tested for antiviral activity in an encephalomyocarditis 
(EMC) virus plaque reduction assay in mouse L cells using 
murine IFNa/f l  as a standard. Further purification was by 
immunoaffinity chromatography using monoclonal anti- 
bodies to muIFNa, muIFNfl and muIFN T coupled to 
Sepharose 4B pre-equilibrated with PBS. Pools of the 
fractions eluted from the Blue Sepharose column in either 
1.5 M NaC1 in PBS or 40% v /v  ethylene glycol in 1.5 M 
NaC1 in PBS were dialysed against PBS using Spectrapor 
3 membrane tubing (MW cut-off 3500) and then applied to 
the immunoaffinity columns at a flow rate of 1 ml/min. 
The columns of antibodies to muIFNa and muIFNfl were 
washed with 20 mM phosphate plus 500 mM NaCl (pH 
7.5). Fractions of 1 ml volume were eluted in 100 mM 
citrate plus 1.0 M NaC1 (pH 2.2), and then neutralised by 
addition of 1 M Tris (pH 10). The columns of antibodies to 
mulFN T were washed with 10 mM phosphate plus 500 
mM NaC1 (pH 8.0). Elution buffer consisted of 20 mM 
phosphate plus 500 mM NaC1 (pH 12.0). The 1-ml frac- 
tions collected were neutralised with 1 M PBS (pH 7.0). 
All procedures were carried out at 4°C. The through 
fraction from the anti-muIFNa columns was loaded onto 
an anti-muIFNfl column and the through fraction from 
this, loaded onto an anti-muIFN T column. The final 
through fraction was dialysed using Spectrapor 3 mem- 
brane tubing, against 0.01% v /v  trifluoroacetic acid 
brought to pH 7 with ammonia and then freeze-dried. 
Freeze-dried fractions were dissolved in 500 /zl of 10 mM 
Tris-HC1 (pH 7.5) and applied to a Q Sepharose Fast Flow 
(Pharmacia) column pre-equilibrated with 10 mM Tris-HC1 
(pH 7.5) at room temperature. A gradient of 0 to 525 mM 
NaC1 in 10 mM Tris (pH 7.5) was used for elution at a 
flow rate of 30 ml /h and 1-ml fractions were collected 
and tested for interferon activity by EMC virus plaque 
reduction assays. The peak fractions from the Q Sepharose 
column showed one single band when analysed by SDS- 
PAGE and an antiviral activity of 3.6 X 10 7 NIH reference 
units/mg protein. 
Amino acid sequencing. For direct sequencing, pooled 
fractions from the Q Sepharose peak were subjected to 
SDS-PAGE separation and electroblotting onto Problott 
[9]. Only one band was visible after staining with 
Coomassie blue. This was cut from the membrane and 
transferred to the protein sequencer in a cartridge designed 
for immobilon (PVDF) blotted samples. For sequence 
analysis of peptides from cyanogen bromide (CNBr) di- 
gests [10], samples were reduced with 0.2 M 2-mercapto- 
ethanol (2 h at 30°C) and lyophilised. They were then 
redissolved in 50% v /v  formic acid containing CNBr 
(approx. 100-fold excess over methionine residues), incu- 
bated under nitrogen for 24 h at 4°C in the dark, then 
diluted to a final concentration of 5% formic acid before 
lyophilisation. Peptides were purified by running 12.5% 
SDS-PAGE gels and electroblotting onto Problott [9]. The 
intact protein and the peptides obtained from digestion 
were sequenced on Applied Biosystems 470A gas-phase 
and 477A pulsed liquid-phase protein sequencers using 
recommended reagents with 120A on-line phenylthio- 
hydantoin (PTH)-amino acid analyzers. Data collection 
and analysis were performed with an Applied Biosystems 
900A module calibrated with 25 pmol PTH-amino acid 
standards [ 11 ]. 
Control IFNs and antibodies. The mulFNot A [12], a 
recombinant IFN derived from cDNA and of which no 
natural counterpart is known, was expressed in Es- 
cherichia coli RRI bacterial cultures containing the p 
mulFNaA/pRK clone under the control of a pL promotor 
and immunoaffinity purified to a specific activity of 1 × 
108 NIH reference U/mg protein. Natural murine 
IFNt~/fl, batch 343 (a gift from Dr I. Gresser), was from 
Balb-c mouse fibroblasts infected with Newcastle Disease 
Virus, purified by affinity chromatography and brought o 
a specific activity of 1 × 107 NIH reference U/mg pro- 
tein. A monoclonal antibody (MCA-MIFNc~ MA-4) which 
recognises all known murine IFNas [13] was a gift from 
Dr Y. Kawade and from the Yamara Shoyu Co. Another 
monoclonal antibody to mulFNa and monoclonal antibod- 
ies to mulFNfl and to mulFN T were from Holland Bio- 
technology. Antibodies to mulFNa/f l  were an IgG frac- 
tion donated by Dr I. Gresser. Antibodies to mulFNaE 
were raised using the IFN obtained from a Q Sepharose 
fraction. 3000 units were injected twice into C57 B 16 mice 
following standard procedures. The animals were test bled 
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Fig. 1. Isolation of antiviral activity by Blue Sepharose chromatography. 
(A) Fractions from supernatants from untreated confluent-quiescent cells 
kept in SFM for 16 h. (B) Fractions from supernatants from cells treated 
for 4 h with 16.5 /xg/ml poly I:poly C and 33.5 /zg/ml DEAE dextran 
followed by 16 h in SFM. Fractions 1-12 were eluted in 1.5 M NaCI in 
PBS. Fractions 13-20 were eluted in 1.5 M NaC1 in PBS plus 40% v /v  
ethylene glycol. 
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Fig. 2. Isolation of antiviral and growth inhibitory activity by ion exchange chromatography. Fractions 16, 17 and 18 of Fig. IB were pooled, depleted of 
factors that bind to columns of antibodies to mulFNa/f l /y  and applied to a Q Sepharose column. Graph represents eluted antiviral activity of individual 
fractions. (a) SDS PAGE and silver staining of fractions 13 plus 14. (b) EMC virus plaque reduction assay of the individual eluted fractions. (c) Effect of 
treatment with fractions 13 plus 14 and of adjacent fractions (11 plus 12 and 15 plus 16) on cell cycle progression of quiecent MEF stimulated by addition 
of 10% fetal calf serum. Histograms represent DNA distribution by FACS analysis. A, cells at seed (GO); B, control cells recorded at 18 h after serum 
stimulation showing cell population shift from GO to S/G2; C, D and E, cells treated with fractions 11 + 12, 13 + 14 and 15 + 16 respectively, recorded at 
18 h after serum stimulation. Note: cell populations in C and D have moved into S/G2 similarly to controls (B), in contrast with the cell population in D. 
for posit ive reaction in an EL ISA assay and then boosted. 
The IgG fraction was then purif ied on DE-52 ion exchange 
cellulose. Control antibodies were an IgG fraction from 
non- immunised mice.  
3. Resul ts  
Initial purification by Blue Sepharose fractionation 
demonstrated that antiviral activity was isolated in two 
separate peaks both under conditions of  constitutive ex- 
pression (Fig. 1A) and after poly I:poly C induction (Fig. 
1B). The first peak was eluted in 1.5 M NaC1, whereas the 
second required addition of  40% ethylene glycol,  indicat- 
ing stronger affinity for the column. Identif ication of  the 
antiviral activity by means of  antibodies to mulFNs  a, fl 
and 7 showed that whi le  the activity of  the first peak 
could be removed by passages through columns of  anti- 
bodies to muIFNa and fl, no detectable activity could be 
removed from the second peak regardless o f  the antibody 
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Fig. 3. Peptide sequences of muIFNaE and of other murine IFNo~s deduced from cDNAs. The sequence of the three cyanogen bromide fragments 
commenced at residues 22, 102 and 153. Residues 101 and 152 (both methionines) are included in the alignment o indicate that many possible isoforms 
can be eliminated since sequence could only be obtained if there is a methionine at the appropriate position for CNBr cleavage. 
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Fig. 4. Inhibition of MEF replication by IFNs. (O)  Untreated control 
cells; cells treated with 500 I.U./ml of (0 )  natural mulFNot//3; (A) 
mulFNot A; (11) mulFNotE. Data plotted are based on several experi- 
ments. Standard error ranged from + 3.3 to + 5.1. 
used (anti-a, anti-/3 and anti-'y), thus pointing to signifi- 
cant epitopal differences. Also it was found that none of 
the activity of the first peak, but all that of the second, was 
destroyed by pH lower than 5.5. Further purification of the 
acid labile fraction following sequential immunoaffinity 
exclusion from columns of antibodies to muIFNa, muIFN/3 
and muIFNT, was by ion exchange fractionation on a Q 
Sepharose column at pH 7.5. Fig. 2 shows that antiviral 
activity was eluted in a single peak and that the two top 
fractions of the peak (fr. 13 + 14), where only one compo- 
nent could be detected (inset a) and where most of the 
antiviral activity resided (inset b), had the ability to impede 
cell progression through the cycle as demonstrated by the 
reduced development of the S-G2 population (inset c, 
histogram D). Both the antiviral and the antiproliferative 
activity of the isolated peak was removed by pH lower 
than 5.5. 
Molecular characterisation u equivocally assigned the 
isolated murine embryonic interferon to the muIFNa fam- 
ily. Direct amino acid sequence analysis gave a sequence 
of 28 amino acids (first peptide of Fig. 3, notation 
muIFNaE 2), demonstrating that the N-terminus of the 
protein was not blocked. Comparison with the correspond- 
ing region of known muIFNas deduced from cDNAs 
showed identity with muIFNa 1 and muIFNaA and exten- 
sive homology with the other types (Fig. 3). Peptides from 
CNBr digests gave three sequences of 7, 22 and 6 amino 
acids. The first (RRLSPLS) corresponded to the terminal 
part of the 28 amino acid peptide obtained by direct 
sequencing. The other two, 22 and 6 amino acids, showed 
differences from the corresponding amino acids of 
2 This notation will be maintained throughout the text. 
Table 1 
Percent reduction of IFN antiviral activity by anti-IFN antibodies 
IFN (10 U/ml) Anti-mulFNc~ [13] Anti-mulFNaE 
(neutralizing U/ml) (neutralizing U/ml) 
l0 100 1000 10 100 1000 
mu IFNaA 76 100 100 32 97 100 
mu IFNa E 26 42 80 40 100 100 
10 U of IFN were incubated with scalar doses of antibodies in 1-ml 
volumes for 1 h at 37°C and then assessed for EMC virus plaque 
reduction in triplicate cultures. 
mulFNa 1 at position 2, 8 and 15 of the longer peptide and 
at position 6 of the other peptide and identity with the 
corresponding sequences of recombinant mulFNaA (Fig. 
3). As this analysis is based on 58 out of 167 possible 
residues, we examined in parallel the isolated embryonic 
IFN and the recombinant mulFNaA for key properties. 
Fig. 4 shows that the antiproliferative activity of the two 
differed, as that of the embryonic interferon was more 
marked than that of recombinant mulFNa A which was 
instead similar to that of the natural muIFNafl. Also, as 
shown in Table 1, a monoclonal antibody that neutralises 
all known muIFNas [13] promptly neutralised the antiviral 
activity of the recombinant IFNaA but had a lesser effect 
on muIFNaE, in accord with the low affinity shown by 
the latter on immunoaffinity columns. Antibodies to 
muIFNaE had a similar effect in both cases. We also 
found that, in contrast to mulFNaE, recombinant 
muIFNaA was retained on columns of antibodies to 
muIFNa s and that it was acid-stable. 
4. Discussion 
The present report identifies a constitutive murine IFNa 
subtype whose properties include an antiproliferative effect 
more marked than that of other murine IFNa s and differ- 
ing physico-chemical properties. Although its antiprolifera- 
tive activity and its embryonic derivation might suggest a
specialised function in developmental differentiation, we 
found that mulFNaE is also released by lung fibroblasts 
from young adult mice (data not shown). On the other 
hand, it should be noted that IGF II, a growth factor with a 
likely role in embryogenesis [14,15], retains a degree of 
expression in the differentiated tissues [16,17]. Respon- 
siveness of the embryonic ell to a given factor may 
therefore be of importance. 
The acid lability of muIFNaE characterises a physico- 
chemical property also noted in the human system where 
an acid-labile IFN activity neutralizable by antibodies to 
IFNas, but not otherwise characterized and of unknown 
antiproliferative activity, has been reported [18-20]. In the 
case of muIFNa E, affinity for antibodies which recognise 
mulFNa s is weak. IFNaE is not retained on anti-mulFNa 
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antibody columns and it is not efficiently neutralised by 
antibodies to the mulFNas.  This indicates ignificant epi- 
tope differences from other mulFNa molecules. Further 
differences are indicated by the strong binding affinity to 
Blue Sepharose while the loss of biological activity at low 
pH may relate to changes in quaternary constraints and/or  
to rearrangement of the tertiary structure not occurring in 
the molecule of the other ~ subtypes. 
Due to difficulties in purification and yield of the 
natural IFNs, most of the IFN sequences known have been 
deduced from cDNAs. The.. extent of the structural identity 
between mulFNceE, a natural IFN, and mulFNaA,  a 
recombinant IFN which is, derived from a cDNA and of 
which no natural counterpart is known, is at present unde- 
termined. Their biological and physico-chemical diversities 
are compelling evidence of molecular differences, but it 
may not be ruled out that, despite their differences, the two 
molecules are the product of the same gene as it cannot be 
excluded that when a natural protein, such as mulFNceE, 
is expressed in recombinant form in a bacterial system, 
differences in post-translational modifications, reflected in 
physico-chemical nd biological properties, might occur. 
However, it is of interest that the growth inhibitory activity 
of the recombinant mulFNaA is comparable to that of the 
natural mu lFNa/ /3  (Fig. 4) in contrast to the more marked 
antiproliferative activity of the natural mulFNaE.  
Whether an interferon comparable to the one we de- 
scribe also exists in the human system is not known. In 
view of the stronger antiproliferative activity of mulFNa E, 
our findings lend support o the quest for new natural IFN 
species in addition to th,~se obtainable by recombinant 
technology. 
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